US · Healthcare · Biotechnology
EPS came in at 6.34 against a street estimate of 4.66 — a beat of 36.1%.
Analysts rate Jazz Pharmaceuticals PLC a buy (16 buy, 2 hold, 0 sell out of 18) with an average price target of $266.90.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.90% |
| Vanguard Portfolio Management, LLC | 4.75% |
| Capital World Investors | 4.26% |
| Vanguard Capital Management, LLC | 4.22% |
| LSV Asset Management | 3.80% |
| FMR Inc | 3.62% |
| Franklin Resources Inc | 3.12% |
| Dimensional Fund Advisors, Inc. | 3.02% |
| Document | Date |
|---|---|
| Shareholder vote results · Q3 2026 | 2026-07-24 |
| Proxy statement · Q3 2026 | 2026-06-08 |
| Board / officer change · Q2 2026 | 2026-05-29 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Annual report FY2025 | 2026-02-24 |
| Results announced · Q1 2026 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Jazz Pharmaceuticals PLC — free to start.
Google PlayApp StoreData updated 2026-08-05.